Free tool
FAERS Monitor: Pepcid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019462 or its brand name (Pepcid, Famotidine). Reports on generic versions are filed under their own applications.
Reports
108,916
Serious
72,067
66% of reports
Hospitalization
36,851
Death reported
10,362
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea7,536
- fatigue7,230
- diarrhoea6,752
- off label use5,562
- dyspnoea5,538
- chronic kidney disease5,512
- drug ineffective5,229
- headache5,172
- pain4,635
- vomiting4,570
- dizziness4,268
- acute kidney injury4,134
- death3,825
- pneumonia3,658
- renal failure3,580
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,480 |
| 2005 | 1,344 |
| 2006 | 1,306 |
| 2007 | 1,066 |
| 2008 | 1,323 |
| 2009 | 1,278 |
| 2010 | 1,762 |
| 2011 | 2,421 |
| 2012 | 3,117 |
| 2013 | 1,821 |
| 2014 | 2,162 |
| 2015 | 3,445 |
| 2016 | 4,042 |
| 2017 | 4,323 |
| 2018 | 5,599 |
| 2019 | 6,908 |
| 2020 | 8,543 |
| 2021 | 8,397 |
| 2022 | 8,912 |
| 2023 | 8,921 |
| 2024 | 10,265 |
| 2025 | 11,235 |
| 2026 | 9,239 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,945,243 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 5,512 | 15.0 | 14.6 | 67,163 |
| acute kidney injurySignal | 4,134 | 5.3 | 5.2 | 14,263 |
| renal failureSignal | 3,580 | 5.3 | 5.2 | 12,302 |
| pneumoniaSignal | 3,658 | 2.2 | 2.1 | 2,390 |
| diarrhoeaSignal | 6,752 | 2.0 | 2.0 | 3,605 |
| dyspnoea | 5,538 | 1.9 | 1.8 | 2,393 |
| vomiting | 4,570 | 1.9 | 1.8 | 1,925 |
| nausea | 7,536 | 1.8 | 1.8 | 3,011 |
| fatigue | 7,230 | 1.8 | 1.8 | 2,648 |
| dizziness | 4,268 | 1.7 | 1.6 | 1,131 |
| headache | 5,172 | 1.6 | 1.6 | 1,182 |
| pain | 4,635 | 1.5 | 1.4 | 688 |
| off label use | 5,562 | 1.2 | 1.2 | 244 |
| death | 3,825 | 0.9 | 0.8 | 95 |
| drug ineffective | 5,229 | 0.8 | 0.7 | 400 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.